1. Home
  2. ACHV vs SGMT Comparison

ACHV vs SGMT Comparison

Compare ACHV & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Achieve Life Sciences Inc.

ACHV

Achieve Life Sciences Inc.

HOLD

Current Price

$4.22

Market Cap

231.0M

Sector

Health Care

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$6.64

Market Cap

204.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACHV
SGMT
Founded
N/A
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
231.0M
204.2M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
ACHV
SGMT
Price
$4.22
$6.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
9
Target Price
$15.50
$27.00
AVG Volume (30 Days)
828.7K
814.3K
Earning Date
03-10-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.84
$1.73
52 Week High
$6.03
$11.41

Technical Indicators

Market Signals
Indicator
ACHV
SGMT
Relative Strength Index (RSI) 34.31 58.19
Support Level $4.05 $5.02
Resistance Level $4.49 $6.15
Average True Range (ATR) 0.34 0.43
MACD -0.18 0.04
Stochastic Oscillator 5.82 71.62

Price Performance

Historical Comparison
ACHV
SGMT

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: